Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Signing of Definitive Agreement to Acquire Drug Lab 118 (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Orexigen Therapeutics Inc. OREXQ

Healthcare Drug Manufacturers - Major
"Orexigen is an emerging pharmaceutical company, focusing on developing neuroscience drugs. The company screens older drugs seeking synergistic actions. The company's most advanced drug candidates target obesity."

Recent & Breaking News (OTCPK:OREXQ)

Orexigen Therapeutics Highlights Key Business Priorities for 2017

PR Newswire January 5, 2017

18 Biggest Mid-Day Gainers For Wednesday

Benzinga.com  January 4, 2017

Orexigen Therapeutics Launches "Brains Behind Weight Loss," a Dynamic Patient Focused Campaign to Educate Consumers on the Role of the Brain in Weight Loss

PR Newswire January 3, 2017

15 Stocks With The Highest Forecast Sales Growth

Benzinga.com  December 23, 2016

Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Biologix FZCO for Contrave® (naltrexone HCl / bupropion HCl prolonged release) for Ten Countries in the Middle East

PR Newswire December 19, 2016

Orexigen Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference 2017

PR Newswire December 19, 2016

Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Consilient Health Ltd. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in the UK and Ireland

PR Newswire December 8, 2016

Worst Performing Industries For December 7, 2016

Benzinga.com  December 7, 2016

Orexigen Announces Presentation of Data for OREX-1019, a Preclinical Candidate for the Treatment and Management of Drug Addiction

PR Newswire November 16, 2016

Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant for Contrave® (naltrexone HCl / bupropion HCl extended release) in Australia and New Zealand

PR Newswire November 8, 2016

Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2016

PR Newswire November 3, 2016

Orexigen Therapeutics to Present at 25th Annual Credit Suisse Healthcare Conference

PR Newswire November 2, 2016

Orexigen Therapeutics to Provide Business Update and Discuss Third Quarter 2016 Financial Results on November 3, 2016

PR Newswire October 21, 2016

18 Biggest Mid-Day Gainers For Tuesday

Benzinga.com  August 30, 2016

Mid-Morning Market Update: Markets Mostly Flat; G-III Apparel Misses Q2 Expectations

Benzinga.com  August 30, 2016

Orexigen Shares Up 14% After Commercialization, Distribution Deal With Valeant Canada

Benzinga.com  August 30, 2016

Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant Canada for Contrave® (naltrexone HCl / bupropion HCl extended release)

PR Newswire August 30, 2016

Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant Canada for Contrave® (naltrexone HCl / bupropion HCl extended release)

Canada NewsWire August 30, 2016

Stocks Hitting 52-Week Lows

Benzinga.com  July 26, 2016

Analysts View on Drug Manufacturers - Other Equities - Endo Intl., Teva Pharma, Synergy Pharma, and Orexigen Therapeutics

PR Newswire June 27, 2016